DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration Resistant Prostate Cancer pipeline drug profiles, including Metastatic Castration Resistant Prostate Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Castration Resistant Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Metastatic Castration Resistant Prostate Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Castration Resistant Prostate Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Castration Resistant Prostate cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Metastatic Castration Resistant Prostate Cancer Pipeline treatment landscape of the report, click here @ Metastatic Castration Resistant Prostate Cancer Pipeline Outlook

 

Key Takeaways from the Metastatic Castration Resistant Prostate Cancer Pipeline Report

• DelveInsight’s Metastatic Castration Resistant Prostate Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline treatment therapies.
• The leading Metastatic Castration Resistant Prostate Cancer Companies are working in the market include Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others
• Emerging Metastatic Castration Resistant Prostate Cancer Pipeline Therapies in the various stages of development include olaparib, abiraterone acetate, enzalutamide, ZEN003694, Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel, prednisone, SRF617, zimberelimab, etrumadenant, and others
• On April 2023, Surface Oncology has announced drug named SRF617, etrumadenant, zimberelimab, by the phase 2. This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC). This is a phase 2, open-label, safety and preliminary efficacy trial in patients with mCRPC using the combination of SRF617, etrumadenant (AB928), and zimberelimab (AB122).
• On June 2023, Zenith Epigenetics has announced drug named ZEN003694 and Enzalutamide by the phase 2. This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry.

 

Metastatic Castration Resistant Prostate Cancer Overview

Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT).

 

For further information, refer to the detailed Metastatic Castration Resistant Prostate Cancer Unmet Needs, Metastatic Castration Resistant Prostate Cancer Market Drivers, and Market Barriers, click here for Metastatic Castration Resistant Prostate Cancer Ongoing Clinical Trial Analysis

 

Metastatic Castration Resistant Prostate Cancer Emerging Drugs Profile

• SRF617: Surface Oncology
• Rucaparib: Clovis Oncology
• HP518: Hinova Pharmaceuticals

 

Metastatic Castration Resistant Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 75+ Metastatic Castration Resistant Prostate Cancer companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The Metastatic Castration Resistant Prostate Cancer companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.

 

Request a sample and discover the recent advances in Metastatic Castration Resistant Prostate Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Castration Resistant Prostate Cancer Treatment Landscape

 

Metastatic Castration Resistant Prostate Cancer Therapeutics Assessment 

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Metastatic Castration Resistant Prostate Cancer Therapeutics Market include-

Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.

 

Dive deep into rich insights for drugs for Metastatic Castration Resistant Prostate Cancer Pipeline, click here @ Metastatic Castration Resistant Prostate Cancer Unmet Needs and Analyst Views

 

Scope of the Metastatic Castration Resistant Prostate Cancer Pipeline Report

• Coverage- Global
• Metastatic Castration Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
• Metastatic Castration Resistant Prostate Cancer Therapies- olaparib, abiraterone acetate, enzalutamide, ZEN003694, Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel, prednisone, SRF617, zimberelimab, etrumadenant, and others.
• Metastatic Castration Resistant Prostate Cancer Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Metastatic Castration Resistant Prostate Cancer Merger and acquisitions, Metastatic Castration Resistant Prostate Cancer Licensing Activities @ Metastatic Castration Resistant Prostate Cancer Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Metastatic Castration Resistant Prostate Cancer Executive Summary
3. Metastatic Castration Resistant Prostate Cancer Overview
4. Metastatic Castration Resistant Prostate Cancer Pipeline Therapeutics
5. Metastatic Castration Resistant Prostate Cancer Therapeutic Assessment
6. Metastatic Castration Resistant Prostate cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rucaparib: Clovis Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Surface Oncology: SRF 617
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. REGN 4336: Regeneron Pharamceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. HP 518: Hinova Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Castration Resistant Prostate cancer Key Companies
21. Metastatic Castration Resistant Prostate cancer Key Products
22. Metastatic Castration Resistant Prostate cancer- Unmet Needs
23. Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
24. Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
25. Metastatic Castration Resistant Prostate cancer Analyst Views
26. Metastatic Castration Resistant Prostate cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services